Prince Pharmaceutical Co (ROCO:6935) Total Equity: NT$839 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
60 GF Score
Price NT$30.25
GF Value NT$42.11
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co Total Equity?

Prince Pharmaceutical Co ROCO:6935 +0.33% 60 Total Equity is NT$839 Mil as of Dec. 2025. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.11 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Prince Pharmaceutical Co's total equity for the quarter that ended in Dec. 2025 was NT$839 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Prince Pharmaceutical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co Total Equity Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 602.87 658.38 774.47 722.06 838.68

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 774.47 743.33 722.06 740.69 838.68
ROCO:6935
60GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Prince Pharmaceutical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1503.486-664.811
=839

Prince Pharmaceutical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1503.486-664.811
=839

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$839 Mil mean?
Prince Pharmaceutical Co (ROCO:6935) has a Total Equity of NT$839 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Prince Pharmaceutical Co and its competitors.
Is Prince Pharmaceutical Co's Total Equity too high?
Prince Pharmaceutical Co's current Total Equity is NT$839 Mil. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's Total Equity compare to ZTS and UTHR?
Prince Pharmaceutical Co's Total Equity of NT$839 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Prince Pharmaceutical Co and its competitors. Prince Pharmaceutical Co's current Total Equity is NT$839 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.11, compared to a current price of NT$30.25 — trading 28.2% below its estimated fair value. The current Total Equity is NT$839 Mil. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current Total Equity is NT$839 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$30.25 is trading 28.2% below its estimated GF Value™ of NT$42.11. GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6935:

  • Total Equity: NT$839 Mil
  • GF Value™: NT$42.11 vs. price of NT$30.25 (28.2% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score

Get the complete analysis for ROCO:6935

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.25
Price
NT$42.11
GF Value